Off-Year Re-Pricing Expected to Cover 70% of Listed Products; Special Steps for Unprofitable Drugs, Patented Meds

Nearly 70% of all medicines listed in Japan will be subject to “off-year” re-pricing slated for next April, but special measures will be taken for unprofitable products and certain patented drugs to address inflation and supply disruptions as well as...read more